AR Asset Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

AR Asset Management’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-50,414	Closed	-$5.41M	–	113
2023 Q1	$5.41M	Sell	50,414 -400	-0.8%	-$46K	1.46%	22
2022 Q4	$5.59M	Sell	50,814 -233	-0.5%	-$15.1K	1.59%	20
2022 Q3	$3.01M	Buy	51,047 +1,000	+2%	+$45.8K	0.9%	37
2022 Q2	$1.41M	Buy	50,047 +22,190	+80%	+$643K	0.4%	60
2022 Q1	$1.05M	Hold	27,857	–	–	0.27%	69
2021 Q4	$1.1M	Buy	+27,857	New	+$872K	0.28%	68

Other funds holding RXDX

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

AR Asset Management's RXDX Position: Q2 2023 in Review

AR Asset Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 50,414 shares — an estimated $5.41M sold.

AR Asset Management first reported a position in RXDX in Q4 2021 and held it in 6 quarters. The position peaked at $5.59M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

AR Asset Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
AR Asset Management sold 50,414 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $5.41M.
AR Asset Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2021 and held it in 6 quarters.
AR Asset Management's Prometheus Biosciences, Inc. Common Stock position peaked at $5.59M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on AR Asset Management's 13F filing for Q2 2023, filed 8 Aug 2023.